Apical membrane antigen 1 (AMA-1) is a leading blood-stage malaria vaccine candidate. Consistent with a key role in erythrocytic invasion, AMA-1-specific antibodies have been implicated in AMA-1-induced protective immunity. AMA-1 is also expressed in sporozoites and in mature liver schizonts where it may be a target of protective cell-mediated immunity. Here, we demonstrate for the first time that immunization with AMA-1 can induce sterile infection-blocking immunity against Plasmodium sporozoite challenge in 80% of immunized mice. Significantly higher levels of gamma interferon (IFN-γ)/interleukin-2 (IL-2)/tumor necrosis factor (TNF) multifunctional T cells were noted in immunized mice than in control mice. We also report the first identification of minimal CD8+ and CD4+ T cell epitopes on Plasmodium yoelii AMA-1. These data establish AMA-1 as a target of both preerythrocytic- and erythrocytic-stage protective immune responses and validate vaccine approaches designed to induce both cellular and humoral immunity.
CITATION STYLE
Schussek, S., Trieu, A., Apte, S. H., Sidney, J., Sette, A., & Doolana, D. L. (2013). Immunization with apical membrane antigen 1 confers sterile infection-blocking immunity against plasmodium sporozoite challenge in a rodent model. Infection and Immunity, 81(10), 3586–3599. https://doi.org/10.1128/IAI.00544-13
Mendeley helps you to discover research relevant for your work.